Efficacy of apatinib on multiple advanced-stage nongastric cancers
نویسندگان
چکیده
منابع مشابه
A Review on the Efficacy of Chemotherapy in Locally Advanced Head and Neck Cancers
Background and Aims: Chemotherapy is utilized as a part of combined-modality programs to achieve organ preservation and improve survival in patients with locally advanced head and neck cancer. Combinedmodality protocols can be used in three forms: a) neoadjuvant induction chemotherapy before definitive surgery or radiotherapy; b) concomitant chemoradiotherapy; and c) sequential therapy consisti...
متن کاملEfficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
OBJECTIVE No standard chemotherapy is available for patients with advanced esophageal squamous cell carcinoma (ESCC) who have failed prior first-line chemotherapy. The aim of this study was to evaluate the efficacy and safety of apatinib, an oral VEGFR-2 inhibitor, as salvage treatment for advanced ESCC. PATIENTS AND METHODS After apatinib dosing, the efficacy and toxicity were evaluated in 6...
متن کاملthe effect of creative writing instruction on lexical density of advanced efl learners writing
چکیده ندارد.
15 صفحه اولEfficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study
This prospective study aimed to evaluate the efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma (HCC).The patients with intermediate/advanced HCC, who met predetermined inclusion and exclusion criteria, underwent oral treatment of apatinib 500 mg daily. The drug-related adverse effects were monitored by regular follow-up and workup including laborato...
متن کاملApatinib is effective for treatment of advanced hepatocellular carcinoma
As treatment options for hepatocellular carcinoma (HCC) are currently limited, we evaluated the efficacy and safety of oral apatinib, a VEGFR-2 inhibitor, on patients with advanced HCC. Twenty-two patients from Tianjin Medical University Cancer Institute and Hospital were enrolled for evaluation. Apatinib was administered at 500 mg/day or 250 mg/day continuously. Clinical endpoints were time to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer Research and Therapeutics
سال: 2019
ISSN: 0973-1482
DOI: 10.4103/jcrt.jcrt_24_19